The Japanese Journal of Pharmacology
January 1, 1971
B.d. Gupta, P.c. Dandiya, Mahima Gupta
78 citations
The Open Field Test measures three distinct behaviors—emotional freezing and defecation (driven by autonomic nervous system reactivity), rearing (driven by cortical excitation), and stereotyped ambulation (driven by corpus striatum activity)—each affected differently by drugs. Autonomic depressants reduce freezing; cortical excitants increase rearing; hallucinatory drugs increase ambulation. LSD and iproniazid selectively stimulate ambulation while suppressing rearing and preening. Amphetamine increases rearing while blocking preening and ambulation. Imipramine inhibits preening without affecting ambulation or rearing. This study extends the approach to methyl phenidate, pentylene tetrazol, mescaline, caffeine, and pargyline to draw conclusions about pharmacological manipulation of Open Field performance.
The Japanese Journal of Pharmacology
January 1, 1958
Hiroshi Takagi, Shigeru Yamamoto, Shuji Takaori et al.
11 citations
Lysergic acid diethylamide (LSD-25) was first synthesized by A. Hofmann in 1943, who noted vertigo and restlessness. Small doses were later reported to produce schizophrenic-like symptoms including thought and speech disturbances, mood changes, hallucinations, and delusions. Gaddum and Woolley demonstrated that LSD antagonizes serotonin in the brain. Meanwhile, chlorpromazine and reserpine showed therapeutic psychiatric effects. The authors used electrophysiological methods to study LSD and reserpine's actions on the central nervous system, recording potential changes from afferent stimulation, and aimed to trace antagonism between LSD and chlorpromazine or reserpine.
The Japanese Journal of Pharmacology
January 1, 1983
Tsuneyuki Yamamoto, Naoe Tazoe, Showa Ueki et al.
9 citations
Zotepine, a new neuroleptic, potently inhibits head-twitch induced by L-5-hydroxytryptophan, mescaline, and 2,5-dimethoxy-4-methylamphetamine in mice and rats, similar to haloperidol and the serotonin receptor blocker cyproheptadine. The results indicate zotepine has a potent anti-hallucinogenic effect.
The Japanese Journal of Pharmacology
January 1, 1992
Tsuneyuki Yamamoto, Masuo Ohno, Shin‐ichi Yatsugi et al.
7 citations
In mice, several drugs being tested as potential nootropics reduced the number of head-twitches caused by mescaline (100 mg/kg). Idebenone (32 and 100 mg/kg), minaprine (0.32–10 mg/kg), and nebracetam (100 mg/kg) significantly suppressed this response. Cholinesterase inhibitors—tetrahydroaminoacridine (1 and 10 mg/kg), NIK-247 (10 and 18 mg/kg), and physostigmine (0.32 mg/kg)—also reduced the head-twitches. The findings suggest that activating cholinergic pathways, either directly or indirectly, may help inhibit mescaline-induced head-twitches in this animal model.
The Japanese Journal of Pharmacology
January 1, 1983
Tsuneyuki Yamamoto, Naoe Tazoe, Showa Ueki et al.
2 citations
Zotepine, a new neuroleptic, potently inhibits head-twitch induced by L-5-hydroxytryptophan, mescaline, and 2,5-dimethoxy-4-methylamphetamine in mice and rats, similar to haloperidol and the serotonin receptor blocker cyproheptadine. The results indicate that zotepine has a potent anti-hallucinogenic effect.
The Japanese Journal of Pharmacology
January 1, 1992
Tsuneyuki Yamamoto, Masuo Ohno, Shin‐ichi Yatsugi et al.
1 citation
In mice, several nootropic candidates reduced head-twitches caused by mescaline. Idebenone, minaprine, and nebracetam significantly lowered the number of mescaline-induced head-twitches. Cholinesterase inhibitors, including tetrahydroaminoacridine, NIK-247, and physostigmine, also suppressed this response. These findings suggest that direct or indirect activation of the cholinergic system may play a role in inhibiting mescaline-induced head-twitches.